Genelux Co. (NASDAQ:GNLX - Get Free Report) shares dropped 1.3% during trading on Friday . The company traded as low as $3.76 and last traded at $3.93. Approximately 93,061 shares traded hands during mid-day trading, a decline of 53% from the average daily volume of 199,940 shares. The stock had previously closed at $3.98.
Analyst Ratings Changes
Separately, HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Genelux in a research report on Tuesday. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Genelux currently has an average rating of "Buy" and an average target price of $18.25.
Read Our Latest Analysis on Genelux
Genelux Stock Down 12.6 %
The stock has a market cap of $117.43 million, a price-to-earnings ratio of -3.58 and a beta of -1.41. The business's 50 day simple moving average is $4.00 and its 200 day simple moving average is $3.09.
Hedge Funds Weigh In On Genelux
Institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its position in Genelux by 39.7% during the 3rd quarter. Geode Capital Management LLC now owns 316,160 shares of the company's stock worth $749,000 after buying an additional 89,854 shares during the period. Marshall Wace LLP increased its position in Genelux by 51.4% during the fourth quarter. Marshall Wace LLP now owns 156,058 shares of the company's stock worth $368,000 after acquiring an additional 52,958 shares during the period. LPL Financial LLC raised its stake in Genelux by 72.3% in the 4th quarter. LPL Financial LLC now owns 94,144 shares of the company's stock worth $222,000 after purchasing an additional 39,516 shares in the last quarter. XTX Topco Ltd bought a new stake in Genelux in the 3rd quarter valued at about $59,000. Finally, D.A. Davidson & CO. bought a new position in shares of Genelux during the fourth quarter worth approximately $51,000. Institutional investors and hedge funds own 37.33% of the company's stock.
Genelux Company Profile
(
Get Free Report)
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
Read More
Before you consider Genelux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genelux wasn't on the list.
While Genelux currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
